Deutsche Bank Maintains Option Care Health (OPCH) Buy Recommendation

Deutsche Bank kept a Buy on Option Care Health (OPCH) on Dec. 9, 2025, with an average one‑year analyst price target of $35.70 (range $27.27–$42.00), implying roughly 16.7% upside from the $30.59 close; company projections show annual revenue of $5,118MM (down 7.46%) and non‑GAAP EPS of $1.12. Institutional positioning is broad but slightly softened: 856 funds hold OPCH (down seven holders), total institutional shares fell 1.08% to 203.4M, while average portfolio weight rose to 0.23%; options put/call ratio is 0.51, signaling a net bullish bias. Major managers have mixed moves—Wellington and Durable Capital trimmed stakes, Fuller & Thaler increased its holding—highlighting active repositioning ahead of fundamentals and analyst expectations (source: Fintel).

Analysis

Deutsche Bank maintained a Buy on Option Care Health (OPCH) on December 9, 2025, while the one-year consensus analyst price target averaged $35.70 as of December 6, implying roughly 16.7% upside from the $30.59 close; analyst targets range widely from $27.27 to $42.00. Company-level projections shown in the report indicate projected annual revenue of $5,118MM, down 7.46% year-over-year, and projected annual non-GAAP EPS of $1.12, which together suggest revenue contraction with modest profitability expectations.

Institutional positioning is broad but softening: 856 funds report positions (down seven holders), total institutional shares fell 1.08% to 203.385M shares, while average portfolio weight increased to 0.23% (up 5.58%), reflecting active rebalancing rather than one-directional conviction. Major managers diverged—Wellington and Durable Capital trimmed shares and allocations, Fuller & Thaler materially increased its holding—and the options put/call ratio of 0.51 points to a mildly bullish derivatives bias.

The juxtaposition of a buy rating and mid-teens upside against a declining revenue baseline and mixed institutional flows creates a conditional investment case: upside is analyst-driven but dependent on near-term stabilization of revenues or clear EPS beat-and-raise signals. Key risks are continued revenue compression and further portfolio reallocation by large holders; monitoring upcoming earnings, 13F filings and options flow will be critical to validate the buy-side thesis.

Key Decisions for Investors

• Consider a modest, size-constrained buy or add-on weakness to capture the ~16.7% analyst-implied upside while limiting exposure to revenue risk
• Monitor the next quarterly report for revenue trajectory versus the projected $5,118MM and non-GAAP EPS against the $1.12 projection before increasing position size
• Track 13F filings and large-holder activity (Wellington, Durable Capital, Fuller & Thaler) and options flow (put/call ~0.51) as real-time sentiment indicators and adjust exposure if institutional selling accelerates
• If risk tolerance is low, wait for evidence of revenue stabilization or a narrower analyst target range before committing incremental capital